Protagonist Therapeutics/$PTGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protagonist Therapeutics
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Ticker
$PTGX
Sector
Primary listing
Employees
132
Headquarters
Website
PTGX Metrics
BasicAdvanced
$6.3B
-
-$2.05
2.25
-
Price and volume
Market cap
$6.3B
Beta
2.25
52-week high
$105.69
52-week low
$39.60
Average daily volume
754K
Financial strength
Current ratio
12.71
Quick ratio
12.585
Long term debt to equity
1.308
Total debt to equity
1.679
Profitability
EBITDA (TTM)
-156.847
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-282.83%
Operating margin (TTM)
-343.63%
Effective tax rate (TTM)
-0.65%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-13.99%
Return on equity (TTM)
-20.18%
Valuation
Price to revenue (TTM)
136.593
Price to book
10.07
Price to tangible book (TTM)
10.07
Price to free cash flow (TTM)
112.078
Free cash flow yield (TTM)
0.89%
Free cash flow per share (TTM)
0.882
Growth
Revenue change (TTM)
-89.41%
Earnings per share change (TTM)
-148.46%
3-year revenue growth (CAGR)
20.07%
3-year earnings per share growth (CAGR)
-7.62%
10-year earnings per share growth (CAGR)
-28.57%
What the Analysts think about PTGX
Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.
PTGX Financial Performance
Revenues and expenses
PTGX Earnings Performance
Company profitability
PTGX News
AllArticlesVideos
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
Accesswire·3 days ago
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Business Wire·3 weeks ago
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Accesswire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protagonist Therapeutics stock?
Protagonist Therapeutics (PTGX) has a market cap of $6.3B as of March 21, 2026.
What is the P/E ratio for Protagonist Therapeutics stock?
The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 0 as of March 21, 2026.
Does Protagonist Therapeutics stock pay dividends?
No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of March 21, 2026.
When is the next Protagonist Therapeutics dividend payment date?
Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) has a beta rating of 2.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.